Veracyte, Inc.
Veracyte is a molecular diagnostics company that provides genomic solutions for the diagnosis and management of cancer and other diseases.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Veracyte’s stock, with a target price of $40.14, indicating growth potential.
Financial Health
Veracyte is performing well with strong revenue and profit margins, indicating healthy business operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring VCYT
Liquid-Biopsy Diagnostics
These innovative companies are developing revolutionary blood tests that can detect cancer earlier and more accurately than ever before. Carefully selected by healthcare investment experts, this collection represents the forefront of non-invasive diagnostics poised to transform the multi-billion dollar oncology market.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Adoption and Revenue
Expanded clinician uptake and broader insurance coverage can drive revenue, though reimbursement shifts may affect results.
International Expansion
Growing presence outside the US can open new markets, but local regulation and payer systems add complexity.
Data and Innovation
Proprietary genomic data and continued R&D can support differentiation, though competitors and tech change pose risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
